Navigation Links
Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
Date:12/28/2009

acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax(TM), which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax(TM) has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax((TM)) will also be the subject of a recent $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including SGX201, orBec(®) and LPM((TM)), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting prec
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
2. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sep. 03, 2015 Research ... the "Investigation Report on China,s Entecavir Market, 2010-2019" ... of people infected with hepatitis B virus (HBV) exceeds ... which 20-30 million suffering from chronic Hepatitis B. About ... damage and liver cancer caused by chronic Hepatitis B, ...
(Date:9/3/2015)... 2015 Research and Markets ... "Investigation Report on China,s Raloxifene Market, 2010-2019" ... statistics, over 200 million people suffer from osteoporosis in ... China , 50% have low bone ... women aged 60 and above. Raloxifene (raloxifene hydrochloride), ...
(Date:9/3/2015)... China,s startup business ... a wearable medical device that can continuously monitor the ... safety guidance for pregnant women. The device will debut ... which measures 4 centimeters in diameter, is as thin ... than an Apple earphone cord. The small and compact ...
Breaking Medicine Technology:China Entecavir Market Report 2010-2019 2Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2
... MINNEAPOLIS, Oct. 21 In conjunction with National ... Technologies Inc. and Your Safety Company have announced ... Cardiac Arrest Foundation for every HeartSine® samaritan® PAD ... Cardiac Arrest Foundation before December 31, 2009. , ...
... Symmetry Medical Inc. (NYSE: SMA ), a leading independent ... other medical markets, announced today that it will release third ... 2009 before the market opens on Thursday, November 5, 2009. ... a.m. ET on Thursday, November 5, 2009. , A ...
Cached Medicine Technology:HeartSine and Your Safety Company to Donate a Portion of Sales Proceeds to Sudden Cardiac Arrest Foundation 2Symmetry Medical to Report Third Quarter 2009 Financial Results on November 5, 2009 2
(Date:9/3/2015)... New York (PRWEB) , ... September 03, 2015 , ... ... the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, ... , Dr. Winchell is a nationally renowned expert in care for the critically injured ...
(Date:9/3/2015)... ... September 03, 2015 , ... As a result of the ... employer-sponsored health insurance plans, more employers are moving to a self-funded model for ... the 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Hunters Creek ... Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited ... for friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... ... September 03, 2015 , ... “We wish to ... impact the delicate life balance between work and leisure to the benefit of ... Leaptrott, CEO , A LifeMinder Plus® Emergency Care Document Set duly executed set ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic comedy film ... Amazon and will be released on DVD early next year, by Maverick ... Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and Confused.” ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2
... Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... that its second quarter results will be made public on ... will hold its quarterly conference call with investors to discuss ... day. , , The public may access the conference ...
... 2009 - (BRONX, NY) - Elevated insulin levels in ... cancer in postmenopausal women, according to researchers at Albert ... are published in the online version of the ... risk for postmenopausal women has previously been linked to ...
... A state budget based entirely on cuts will accelerate ... state when the recession is over, according to a labor ... House leaders recently announced their intention to produce a no ... to Senate Bill 850, a bare-bones budget passed by the ...
... Foundation commends the nomination by President Obama of Francis Collins, ... of Health (NIH). , , "The CF Foundation is ... of the gene responsible for cystic fibrosis, may lead the ... is being highlighted by President Obama," said Robert J. Beall, ...
... , SAN DIEGO, July 9 CardioDynamics (Nasdaq: CDIC ... today reported financial results for fiscal second quarter 2009. Highlights ... growth compared with Q2 2008, the third consecutive quarter of year ... Highlights of Second Quarter 2009 Compared with Second Quarter 2008 ...
... , FT. LEE, N.J., July 9 Red wine (resveratrol) pills ... of cardiologists wants to lead the way for patients and consumers ... U.S. cardiologists to do so. , , (Photo: ... the heart-healthy properties of red wine pills, a local cardiology group ...
Cached Medicine News:Health News:Quest Diagnostics To Release Second Quarter Financial Results 2Health News:Einstein scientists link elevated insulin to increased breast cancer risk 2Health News:Deep Budget Cuts Will Add to Unemployment Rolls at Wrong Time 2Health News:Deep Budget Cuts Will Add to Unemployment Rolls at Wrong Time 3Health News:CF Foundation Supports President Obama's Nomination of Francis Collins, M.D., Ph.D., as New NIH Director 2Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 2Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 3Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 4Health News:CardioDynamics Reports Second Fiscal Quarter 2009 Results 5Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 2Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 3Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 4
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. The ... which is non-toxic and non-antigenic. Implants ... minimize scleral intrusion. These implants are ...
... Size: 7.5 x 2.75 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 12.0 mm....
For use with E5381 600 Circling Band (40 style)....
Medicine Products: